Tyra Biosciences to Participate in Upcoming Investor Conferences
PR Newswire•05/11/2026•16:05 ET
0
Key Highlights
- ➤Tyra Biosciences (TYRA) to hold investor meetings at two healthcare conferences
- ➤Jefferies presentation scheduled for November 16, 2026, at 11:30 AM GMT
- ➤Live Jefferies webcast and replay available through Tyra’s investor website
- ➤Lead dabogratinib targets FGFR3-driven cancers and achondroplasia
- ➤TYRA-430 and TYRA-200 are advancing in clinical studies for solid tumors
Tyra Biosciences to Participate in Upcoming Investor Conferences PR Newswire
CARLSBAD, Calif., Nov. 5, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences:
Get started
Create a free account to read the full story.